Transcreener dAMP Exonuclease Assay
The Transcreener dAMP Exonuclease Assay directly measures dAMP produced by exonuclease enzymes as they cleave polynucleotides.
Receive your quote directly from the manufacturer.
The Transcreener dAMP Exonuclease Assay directly measures dAMP produced by exonuclease enzymes as they cleave polynucleotides. These dAMP measurements allow researchers to effectively determine the activity of the enzyme. The assay provides a powerful tool to screen compound libraries for exonuclease modulators to help find new therapies for disease. One example is TREX1, a crucial component of the innate immune response where it acts as the main exonuclease responsible for degrading cytosolic DNA.
How does the Transcreener dAMP Exonuclease Assay Work?
The Transcreener dAMP Exonulcease Assay determines exonuclease enzyme activity by directly measuring dAMP (deoxyadenosine monophosphate, deoxyadenylic acid, deoxyadenylate, or 2'-Deoxyadenosine-5'-monophosphate) that can be produced during biological functions like the degradation of DNA. By directly detecting dAMP in a homogenous format, it is possible to perform screening and enzymatic studies with virtually any enzyme that produces dAMP.
Transcreener dAMP technology uses polyclonal mouse antibodies that selectively bind to dAMP and a far-red fluorescent tracer. As dAMP produced in the reaction competes with the tracer changing the fluorescent properties and providing fluorescent readout.
The Transcreener dAMP Exonuclease Assay is available with an FP fluorescent readout. It is a simple mix-and-read format. Perform your enzyme reaction, add the detection reagents, and measure. The simplicity of the system yields robust results that also make it extremely amiable to HTS.
Interrogating TREX1 with the Transcreener dAMP exonuclease assay
Download this application note to find out how the Transcreener dAMP exonuclease assay is a powerful tool for the discovery of TREX1 antagonists that will accelerate efforts to validate the target pharmacologically, possibly leading to a new class of immune checkpoint inhibitors.
